Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$200.47 USD

200.47
3,531,078

-3.08 (-1.51%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $200.75 +0.28 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View

by Zacks Equity Research

Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.

Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?

by Zacks Equity Research

Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

Top Ranked Value Stocks to Buy for July 23rd

by Zacks Equity Research

Here are four stocks with buy rank and strong value characteristics for investors to consider today, July 23rd

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $68, marking a -0.79% move from the previous day.

Sweta Killa headshot

Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy

by Sweta Killa

With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.

Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?

by Zacks Equity Research

While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.

Is a Beat in Store for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.

AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AbbVie (ABBV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

Kinjel Shah headshot

3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement

by Kinjel Shah

Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.

AC Immune Initiates Phase I Study for Alzheimer's Disease

by Zacks Equity Research

AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.

Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance

by Zacks Equity Research

Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.

Should Value Investors Buy AbbVie (ABBV) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

AbbVie (ABBV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AbbVie (ABBV) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

AbbVie (ABBV) is well positioned to outperform the market, as it exhibits above-average growth in financials.

AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio

by Zacks Equity Research

AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.

J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $70.29 in the latest trading session, marking a +0.01% move from the prior day.

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

by Zacks Equity Research

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

J&J (JNJ) to Kick-Start Pharma Q2 Earnings: A Beat in Store?

by Zacks Equity Research

J&J's (JNJ) cancer drugs should continue to perform well in second-quarter 2019. Generic/biosimilar headwinds will hurt Pharma unit's sales.

Nilanjan Banerjee headshot

Will Patent Woes Boost Pharma Stock Megamergers Further?

by Nilanjan Banerjee

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $71.25 in the latest trading session, marking a +0.04% move from the prior day.

ObsEva Ends Recruitment in Second Uterine Fibroids Study

by Zacks Equity Research

ObsEva (OBSV) completes patient recruitment in the second pivotal phase III study evaluating linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids.

The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon, UnitedHealth, AbbVie, Simon Property and Autodesk

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

by Zacks Equity Research

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.